US23666P1012 - Common Stock
DARE BIOSCIENCE INC
NASDAQ:DARE (4/17/2024, 7:00:01 PM)
Premarket: 0.281 0 (-0.6%)0.2827
-0.2 (-41.7%)
Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. The company is headquartered in San Diego, California and currently employs 25 full-time employees. The company went IPO on 2014-04-10. The firm is engaged in identifying, developing, and marketing a portfolio of differentiated therapies that prioritize women's health and well-being, primarily in the areas of contraception, vaginal health, reproductive health, menopause, sexual health and fertility. Its first product, XACIATO, is a clindamycin phosphate vaginal gel used for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its pipeline includes various other clinical-stage programs, such as Ovaprene, Sildenafil Cream 3.6%, DARE-HRT1, DARE-VVA1, DARE-FRT1 and DARE-PTB1. Its pre-clinical-stage programs include DARE-LARC1, DARE-GML, DARE-LBT, and DARE-RH1. Ovaprene is an investigational hormone-free monthly intravaginal contraceptive. Sildenafil Cream 3.6% is a proprietary cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder (FSAD).
DARE BIOSCIENCE INC
3655 Nobel Dr Ste 260
San Diego CALIFORNIA 92122
P: 18589267655
CEO: Sabrina Martucci Johnson
Employees: 25
Website: https://www.darebioscience.com/
Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session.
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.
Published data shows that Ovaprene was safe and effective in a postcoital test study of 33 women Pivotal Phase 3 contraceptive efficacy clinical study of...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Dare Bioscience (NASDAQ:DARE) just reported results for the fourth quarter of 2...
DARE stock results show that Dare Bioscience beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
Conference Call and Webcast Today at 4:30 p.m. ET...
Here you can normally see the latest stock twits on DARE, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: